EcoDrugPlus

Natriuretic Peptide Receptor 1

Ensembl ID : ENSSPAG00000009651
Gene Symbol: NPR1
2 Cross references
191 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSSPAG00000021993
Gene Symbol: NPR2
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSSPAG00000012345
Gene Symbol: NPR3
3 Cross references
211 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSPAG00000015298
Gene Symbol: LOC103357999
3 Cross references
196 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSSPAG00000006379
Gene Symbol: LOC103353434
3 Cross references
201 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSSPAG00000022755
Gene Symbol: LOC103358203
3 Cross references
197 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSSPAG00000000022
Gene Symbol: LOC103361415
3 Cross references
218 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSSPAG00000022482
Gene Symbol: LOC103364333
3 Cross references
193 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSSPAG00000019783
Gene Symbol: NPY2R
3 Cross references
184 Possible Orthologues:

Neuropeptide Y Receptor Type 2-Like

Ensembl ID : ENSSPAG00000013682
Gene Symbol: LOC103367953
3 Cross references
176 Possible Orthologues:

Neuropeptide Y Receptor Type 4-Like

Ensembl ID : ENSSPAG00000006620
Gene Symbol: LOC103369003
3 Cross references
135 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSSPAG00000003029
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).